Form 4: NEPHROS Director Acquires 8,036 Shares of Common Stock
Insider Transaction Report
NEPHROS Director Oliver Spandow reported the acquisition of 8,036 shares of common stock, increasing his direct beneficial ownership to 122,881 shares.
Summary
- Oliver J. Spandow, a Director of NEPHROS, Inc. (NEPH), acquired 8,036 shares of common stock.
- The transaction occurred on November 10, 2025, at a price of $0 per share, indicating a grant or award.
- Following this acquisition, Mr. Spandow directly beneficially owns 122,881 shares of NEPHROS common stock.
- Mr. Spandow also holds several stock options with various exercise prices ranging from $1.07 to $8.57 and expiration dates extending up to January 1, 2035.
- Some of the stock options have vesting schedules, with shares vesting on dates such as May 14, 2024, January 1, 2025, May 14, 2025, January 1, 2026, May 14, 2026, and January 1, 2027.
Sentiment
Score: 6
Explanation: The filing reports a director's acquisition of common stock, which is generally viewed as a positive signal of confidence, though it is a routine insider transaction filing.
Positives
- Director Oliver J. Spandow increased his direct beneficial ownership in NEPHROS, Inc. by acquiring 8,036 shares of common stock.
- The acquisition at a $0 price suggests a grant or award, which typically aligns management's interests with those of shareholders.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Oliver J. Spandow, a Director of NEPHROS, Inc., acquired 8,036 shares of common stock at a price of $0, likely as part of an equity compensation plan, which constitutes a related party transaction.
Stakeholder Impact
- Shareholders: The acquisition of additional shares by a director can signal confidence in the company's future, potentially aligning the director's interests more closely with those of shareholders.
- Employees: If this transaction is part of a broader equity compensation program, it may reflect the company's strategy to incentivize and retain key personnel, potentially impacting employee morale and alignment.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Vesting date for 2,441 shares of a stock option with an exercise price of $2.14. |
| 01/01/2025 | Vesting date for 2,350 shares of a stock option with an exercise price of $1.47. |
| 05/14/2025 | Vesting date for 2,441 shares of a stock option with an exercise price of $2.14. |
| 11/10/2025 | Transaction date for the acquisition of 8,036 shares of common stock. |
| 11/13/2025 | Signature date of the Form 4 filing. |
| 01/01/2026 | Vesting date for 2,350 shares of a stock option with an exercise price of $1.47. |
| 05/14/2026 | Vesting date for 2,441 shares of a stock option with an exercise price of $2.14. |
| 01/01/2027 | Vesting date for 2,350 shares of a stock option with an exercise price of $1.47. |
| 08/10/2028 | Expiration date for stock option to buy 9,466 shares at $5.5755. |
| 12/19/2028 | Expiration date for stock option to buy 5,161 shares at $5.85. |
| 12/16/2029 | Expiration date for stock option to buy 5,568 shares at $8.57. |
| 01/06/2031 | Expiration date for stock option to buy 6,850 shares at $8.06. |
| 12/14/2031 | Expiration date for stock option to buy 7,062 shares at $6.82. |
| 01/05/2033 | Expiration date for stock option to buy 7,080 shares at $1.07. |
| 05/14/2034 | Expiration date for stock option to buy 7,323 shares at $2.14. |
| 01/01/2035 | Expiration date for stock option to buy 7,050 shares at $1.47. |
Recommendation
holdThis Form 4 reports a routine insider acquisition of shares, likely a grant or award, which generally indicates a director's continued alignment with shareholder interests. However, without additional financial or operational context, this filing alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate as it's a standard disclosure without significant new strategic or financial data.
Keywords
NEPHROS, NEPH, Form 4, insider transaction, stock acquisition, director, beneficial ownership, stock options, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.